SAN CARLOS, Calif., June 3, 2026
Iovance Biotherapeutics has announced that Australia’s Therapeutic Goods Administration (TGA) has granted approval with conditions for Amtagvi® (lifileucel), marking a major advancement in the treatment of advanced melanoma and strengthening the global expansion of innovative cell therapies. The approval represents a historic milestone as Amtagvi becomes the first T-cell therapy approved for a solid tumor cancer in Australia and the first approved treatment option in the country for patients with advanced melanoma who have previously received anti-PD-1 therapy and targeted treatments. The decision underscores the growing importance of personalized cell therapies in oncology and highlights the continued evolution of immunotherapy approaches designed to address significant unmet medical needs in patients with difficult-to-treat cancers.
Landmark Approval Expands Access to Advanced Cell Therapy
The Australian approval allows the use of Amtagvi (lifileucel) for adult patients with unresectable or metastatic melanoma who have previously been treated with a PD-1 blocking antibody and, where applicable, a BRAF inhibitor with or without a MEK inhibitor. Australia has one of the highest melanoma incidence rates globally, with approximately 17,000 new melanoma cases diagnosed annually and more than 1,500 melanoma-related deaths each year, creating an urgent need for additional therapeutic options. The approval provides new hope for patients whose disease has progressed despite existing standards of care.
As a tumor-infiltrating lymphocyte (TIL) therapy, Amtagvi utilizes a patient’s own immune cells extracted from tumor tissue, expanded and activated outside the body, and then reinfused to target and destroy cancer cells. This personalized treatment approach represents a significant advancement in the rapidly expanding field of cell-based cancer immunotherapy.
Clinical Evidence Supports Regulatory Success
Advertisement
The TGA approval was supported by results from the global C-144-01 Phase II clinical trial, which evaluated Amtagvi in patients with advanced melanoma previously treated with anti-PD-1 therapies and targeted treatments when appropriate. The multicenter study assessed efficacy using objective response rate (ORR) and duration of response (DOR), demonstrating meaningful and durable clinical activity in a heavily pretreated patient population. Findings from the study have been published in leading oncology journals, including the Journal for ImmunoTherapy of Cancer and the Journal of Clinical Oncology, providing strong scientific support for the therapy’s clinical benefit.
The approval further validates the potential of TIL-based therapies to deliver long-lasting responses in patients with limited treatment alternatives and reinforces the role of cellular immunotherapy as a transformative modality in cancer treatment.
Strengthening Global Expansion of TIL Therapies
The Australian authorization marks the third global marketing approval for Amtagvi, supporting Iovance’s strategy to expand access to TIL therapies in regions with high rates of advanced melanoma. The company is currently preparing to authorize its first treatment center in Australia while continuing to evaluate opportunities for broader international expansion. Beyond melanoma, Iovance is investigating Amtagvi in additional solid tumors and in the ongoing Phase III TILVANCE-301 trial, which is evaluating the therapy as a frontline treatment for advanced melanoma.
The approval demonstrates increasing global regulatory confidence in personalized cell therapies and highlights the growing momentum behind next-generation immuno-oncology approaches. As healthcare systems seek innovative solutions capable of delivering durable responses in advanced cancers, Amtagvi’s approval is expected to further accelerate adoption of T-cell therapies and establish new standards for personalized cancer care.
Source: Iovance Biotherapeutics press release
